Paolo Barassi
Overview
Explore the profile of Paolo Barassi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
12
Citations
187
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Arici M, Hsu S, Ferrandi M, Barassi P, Ronchi C, Torre E, et al.
Vascul Pharmacol
. 2024 Jul;
155:107295.
PMID: 38985597
No abstract available.
2.
Arici M, Hsu S, Ferrandi M, Barassi P, Ronchi C, Torre E, et al.
J Transl Med
. 2024 Jan;
22(1):77.
PMID: 38243248
Background: The sarcoplasmic reticulum (SR) Ca ATPase (SERCA2a) depression substantially contributes to diastolic dysfunction in heart failure (HF), suggesting that SERCA2a stimulation may be a mechanism-based HF therapy. Istaroxime is...
3.
Maniezzi C, Eskandr M, Florindi C, Ferrandi M, Barassi P, Sacco E, et al.
Acta Physiol (Oxf)
. 2024 Jan;
240(3):e14082.
PMID: 38214033
Aims: The heterozygous phospholamban (PLN) mutation R14del (PLN R14del ) is associated with a severe arrhythmogenic cardiomyopathy (ACM) developing in the adult. "Superinhibition" of SERCA2a by PLN R14del is widely...
4.
Arici M, Ferrandi M, Barassi P, Hsu S, Torre E, Luraghi A, et al.
J Pharmacol Exp Ther
. 2022 Sep;
384(1):231-244.
PMID: 36153005
Heart failure (HF) therapeutic toolkit would strongly benefit from the availability of ino-lusitropic agents with a favorable pharmacodynamics and safety profile. Istaroxime is a promising agent, which combines Na/K pump...
5.
Luraghi A, Ferrandi M, Barassi P, Arici M, Hsu S, Torre E, et al.
J Med Chem
. 2022 May;
65(10):7324-7333.
PMID: 35580334
The stimulation of sarcoplasmic reticulum calcium ATPase SERCA2a emerged as a novel therapeutic strategy to efficiently improve overall cardiac function in heart failure (HF) with reduced arrhythmogenic risk. Istaroxime is...
6.
Torre E, Arici M, Lodrini A, Ferrandi M, Barassi P, Hsu S, et al.
Cardiovasc Res
. 2021 Apr;
118(4):1020-1032.
PMID: 33792692
Aims: Diabetic cardiomyopathy is a multifactorial disease characterized by an early onset of diastolic dysfunction (DD) that precedes the development of systolic impairment. Mechanisms that can restore cardiac relaxation improving...
7.
Ferrandi M, Barassi P, Tadini-Buoninsegni F, Bartolommei G, Molinari I, Tripodi M, et al.
Br J Pharmacol
. 2013 Jun;
169(8):1849-61.
PMID: 23763364
Background And Purpose: Calcium handling is known to be deranged in heart failure. Interventions aimed at improving cell Ca(2) (+) cycling may represent a promising approach to heart failure therapy....
8.
Rocchetti M, Alemanni M, Mostacciuolo G, Barassi P, Altomare C, Chisci R, et al.
J Pharmacol Exp Ther
. 2008 Jun;
326(3):957-65.
PMID: 18539651
PST2744 [Istaroxime; (E,Z)-3-((2-aminoethoxy)imino) androstane-6,17-dione hydrochloride)] is a novel inotropic agent that enhances sarco(endo)plasmic reticulum Ca(2+) ATPase (SERCA) 2 activity. We investigated the istaroxime effect on Ca(2+) handling abnormalities in myocardial...
9.
Micheletti R, Palazzo F, Barassi P, Giacalone G, Ferrandi M, Schiavone A, et al.
Am J Cardiol
. 2007 Jan;
99(2A):24A-32A.
PMID: 17239701
Interventions involving calcium cycling may represent a promising approach to heart failure (HF) therapy because calcium handling is known to be deranged in human and experimental HF. Istaroxime is a...
10.
Ferrandi M, Molinari I, Barassi P, Minotti E, Bianchi G, Ferrari P
J Biol Chem
. 2004 May;
279(32):33306-14.
PMID: 15161929
In addition to inhibition of the Na-K ATPase, ouabain activates a signal transduction function, triggering growth and proliferation of cultured cells even at nanomolar concentrations. An isomer of ouabain (EO)...